research use only

S55746 Bcl-2 inhibitor

Cat.No.S8759

S55746 (S 055746,BCL201) is a novel, orally active BCL-2 specific inhibitor (Ki = 1.3 nM) with poor affinity for BCL-XL and no significant binding to MCL-1, BFL-1 (BCL2A1/A1). The selectivity of this compound for BCL-2 versus BCL-XL ranges from ~70 to 400 folds.
S55746 Bcl-2 inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 710.82

Jump to

Quality Control

Batch: S875901 DMSO]100 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.73%
99.73

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (140.68 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 710.82 Formula

C43H42N4O6

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1448584-12-0 -- Storage of Stock Solutions

Synonyms S 055746,BCL201 Smiles C1CCN2C(=C(C=C2C3=CC4=C(C=C3C(=O)N5CC6=CC=CC=C6CC5CN7CCOCC7)OCO4)C(=O)N(C8=CC=CC=C8)C9=CC=C(C=C9)O)C1

Mechanism of Action

Targets/IC50/Ki
Bcl-2
(Cell-free assay)
1.3 nM(Ki)
In vitro

S55746 occupies the hydrophobic groove of BCL-2. In a panel of hematological cell lines, this compound induces hallmarks of apoptosis including externalization of phosphatidylserine, caspase-3 activation and PARP cleavage. It potently induces RS4;11 cell killing after 72 h of treatment with an IC50 of 71.6 nM and exhibits a much weaker activity in H146 (IC50 = 1.7 μM), a BCL-XL-dependent cell line, which expresses a low level of BCL-2 and high level of BCL-XL. It has no cytotoxic activity on BCL-XL-dependent cells, such as platelets.

In vivo

S55746 administered by oral route daily in mice demonstrates robust anti-tumor efficacy in two hematological xenograft models (RS4;11 and Toledo models) with no weight lost and no change in behavior.

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02603445 Completed
Follicular Lymphoma Mantle Cell Lymphoma
Novartis Pharmaceuticals|Novartis
November 16 2015 Phase 1
NCT02920541 Completed
Acute Myeloid Leukaemia (AML)|Myelodysplastic Syndrome (MDS)
Institut de Recherches Internationales Servier|ADIR a Servier Group company|Servier
January 2015 Phase 1
NCT02920697 Completed
Chronic Lymphocytic Leukaemia (CLL)|B-Cell Non-Hodgkin Lymphoma (NHL)|Multiple Myeloma (MM)
Institut de Recherches Internationales Servier|ADIR a Servier Group company|Servier
March 2014 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map